Rapport therapeutics announces pricing of initial public offering

Boston and san diego, june 06, 2024 (globe newswire) -- rapport therapeutics, inc. (nasdaq: rapp), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, today announced the pricing of its initial public offering of 8,000,000 shares of its common stock at a public offering price of $17.00 per share. rapport's shares are expected to begin trading on the nasdaq global market on june 7, 2024 under the ticker symbol “rapp.” the offering is expected to close on june 10, 2024, subject to the satisfaction of customary closing conditions. in addition, rapport has granted the underwriters a 30-day option to purchase an additional 1,200,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. all of the shares of common stock are being offered by rapport.
RAPP Ratings Summary
RAPP Quant Ranking